

f72nd Annual

Montagna Symposium on the Biology of Skin

Mechanistic Insights into Emerging Therapeutic Platforms

Oct. 16-20, 2025

Program Chair

Anthony Oro, M.D., Ph.D.

Co-Organizers

Aimee Payne, M.D., Ph.D.

Masayuki Amagai, M.D., Ph.D.

Symposium Co-directors

Sancy Leachman, M.D., Ph.D.

Tamia Harris-Tryon, M.D., Ph.D.

Dennis Roop, Ph.D.

Salishan Coastal Lodge

7760 Highway 101

Glenden Beach, OR 97388

Conference Program

Thursday, October 16

2 p.m. – 5:30 p.m.

Arrival and Check-in

4:00 p.m. – 5:30 p.m.

Opening Reception (Heavy Hors d'oeuvres served)

5:30 p.m. – 5:45 p.m.

Welcome and Introductory Comments

Symposium Co-Directors:

Sancy Leachman, M.D., Ph.D. (University of Utah)

Tamia Harris-Tryon, M.D., Ph.D. (University of Texas Southwestern Medical Center)

Program Chair: **Anthony Oro, M.D., Ph.D.** (Stanford University)

5:45 p.m. – 6:45 p.m.

Keynote

Howard Chang, M.D., Ph.D.

Senior Vice President of Global Research and Chief Scientific Officer, Amgen

RNA origin of sex biased immunity

This presentation will describe new mechanistic understandings of why autoimmune diseases preferentially affect women and highlight diagnostic and therapeutic opportunities.

7 p.m.

Dinner On Your Own

8 p.m. – 11p.m. Optional Gathering: Outdoor Firepit

Friday, October 17

7 a.m. – 8 a.m. **Breakfast**

8 a.m. – 8:05 a.m. Announcements

8:05 a.m. – 8:15 a.m. Session 1:

Novel Targets for Engineered Cell Therapies

Session Moderator: **Christoph Ellebrecht, M.D.**

Assistant Professor of Dermatology, University of Pennsylvania

While precision immune therapies have revolutionized blood cancer treatment, new evidence indicates their effectiveness in skin autoimmune and cancers as well. Understanding the mechanistic basis of precision immune therapies and the current patient response remains a gap in knowledge that needs to be addressed.

8:15 a.m. – 8:40 a.m.

Christoph Ellebrecht, M.D.

Assistant Professor of Dermatology, University of Pennsylvania

Controlling T Cell Fate and Function: Therapeutic Applications from Cancer to Autoimmunity

8:40 a.m. – 8:55 a.m.

Discussion

8:55 a.m. – 9:10 a.m.

Farzan Solimani, M.D.

Associate Research Scientist, Columbia University

Engineered T cells for autoimmunity: emerging data from human clinical trials

9:10 a.m. – 9:35 a.m.

Jaehyuk Choi, M.D., Ph.D.

Professor of Dermatology, Director - Center for Cellular Therapies and Cancer Immunology, UT-Southwestern

Genetic Variations Regulating Engineered T-cell Efficacy

9:35 a.m. – 9:50 a.m.

Discussion

9:50 a.m. – 10:05 a.m.

Coffee Break

10:05 a.m. – 10:30 a.m.

Michael Girardi, M.D.

Professor of Dermatology, Yale University

Strategies Overcoming Challenges Targeting T Cell Lymphoma

10:30 a.m. – 10:45 a.m.

Discussion

10:45 a.m. – 11 a.m.

Umber Dube, M.D., Ph.D.

Associate Physician, Dermatology, UC San Diego

The Impact of Hematopoietic Stem Cell-Mediated Ex Vivo Gene Therapy on the Skin in Cystinosis

11 a.m. – 11:15 a.m.

Jonathan Park, M.D., Ph.D.

Resident Physician, Dermatology, Northwestern University Feinberg School of Medicine

Clonal hematopoiesis in primary and CAR T-cell related secondary T-cell malignancies

11:15 a.m. – 11:30 a.m.

Caitlin Frazee, M.S.E.

Ph.D. Graduate Student, Department of Dermatology, Perelman School of Medicine, University of Pennsylvania

Autoantibody-inducible Chimeric Antigen Receptors (CARs): a self-regulating immunotherapy for durable remission in pemphigus vulgaris

Noon – 1:15 p.m.

Lunch

Industry Leaders Panel: *Breakthroughs in Cell and Gene Therapy*

(Key takeaways include: recent breakthroughs in cell therapy, industry-academic partnerships and support for IITs, evaluation of early-stage opportunities for licensing/acquisition)

Facilitator: **William Ju, M.D.**, President, Advancing Innovation in Dermatology

Panelists:

G. Grant Welstead, Ph.D., Vice President, Discovery Biology, Century Therapeutics

Kiren Kresa-Reahl, M.D., Senior Medical Director, Clinical Development, Cabaletta Bio

Ashley Koegel, M.D., Executive Director, Early Clinical Development, Bristol Myers Squibb

Shawn Rose, M.D., Ph.D., Chief Medical Officer, Head of Research and Development, Nkarta

1:15 p.m. – 1:25 p.m.

Session 2:

Tissue Regeneration Therapeutic Approaches

Session Moderator: **Anthony Oro, M.D., Ph.D.**

Professor of Dermatology, Associate Director – Center for Definitive and Curative Medicine, Stanford University

Gaps in our medical armamentarium come from the inability to replace many defective tissues due to genetic disease, injury, excessive fibrosis or age. New approaches exist to generate the appropriate genetically corrected tissue or reduce fibrosis, but clinical scale and delivery to the patient remain important hurdles.

1:25 p.m. – 1:50 p.m.

Anthony Oro, M.D., Ph.D.

Professor of Dermatology, Associate Director – Center for Definitive and Curative Medicine, Stanford University

Manufacturing Multilineage Tissue Replacement Therapies for Genetic Diseases

1:50 p.m. – 2:05 p.m.

Discussion

2:05 p.m. – 2:30 p.m.

Luis Garza, M.D., Ph.D.

Professor of Dermatology, Johns Hopkins University

Cellular therapy to modify skin identity

2:30 p.m. – 2:45 p.m.

Discussion

2:45 p.m. – 3:10 p.m.

Trevor Parry, Ph.D.

VP, Research and Scientific Affairs, Krystal Biotech

A redosable HSV-1-based platform technology for localized gene delivery

3:10 p.m. – 3:25 p.m.

Discussion

3:25 p.m. – 3:40 p.m.

Coffee Break

3:40 p.m. – 4:05 p.m.

Dayan Li, M.D., Ph.D.

Clinical Scholar, Dermatology, Stanford University

Mechanistic insights into fibrosis versus regeneration

4:05 p.m. – 4:20 p.m.

Discussion

4:20 p.m. – 4:35 p.m.

Noha Ahmed, Ph.D.

Post-Doctoral Research Fellow, University of Alabama at Birmingham

Targeting FKBP s to Promote Regenerative Wound Healing

4:35 p.m. – 4:50 p.m.

Edward Eid, M.D.

Basic Life Research Scientist, Dermatology, Stanford Medicine

Enhancing the therapeutic potential of intravenous recombinant collagen VII, a protein replacement therapy, for recessive dystrophic epidermolysis bullosa

4:50 p.m. – 5:05 p.m.

Cory Simpson, M.D., Ph.D.

Assistant Professor, Dermatology, University of Washington School of Medicine

Organotypic models of genetic skin blistering diseases reveal rational therapeutic strategies and guide drug repurposing

5:30 p.m. – 7 p.m.

Dinner and Travel Award Ceremony:

- Society for Investigative Dermatology (SID) Farber Award
- Japanese Society for Investigative Dermatology (JSID) Award
- Korean Society for Investigative Dermatology (KSID) Award
- Taiwanese Society for Investigative Dermatology (TSID) Award
- European Society for Dermatological Research (ESDR) Award
- Molly Kulesz-Martin, Ph.D., Director's Award

7 p.m. – 8 p.m.

Poster Reception and Wine Tasting

Saturday, October 18

7 a.m. – 8 a.m.

Breakfast

8 a.m. – 8:05 a.m.

Announcements

8:05 a.m. – 8:15 a.m.

Session 3:

Novel Immunomodulatory Platforms for Cutaneous Disease

Session Moderator: **Masayuki Amagai, M.D., Ph.D.**

Professor and Chair of Dermatology, Keio University

Director – RIKEN Center for Integrative Medical Sciences

Breaking tissue tolerance forms the basis of tissue rejection and pathogenesis of autoimmune disease, but the mechanisms of immune tolerance and therapeutic targets remain poorly validated. This session addresses a gap in knowledge about small molecule and peptide therapies for immunomodulation.

8:15 a.m. – 8:40 a.m.

Masayuki Amagai, M.D., Ph.D.

Professor and Chair of Dermatology, Keio University

Director – RIKEN Center for Integrative Medical Sciences

Converting Pathogenic Autoimmune T Cells into Antigen-Specific Regulatory T Cells as a Novel Therapeutic Strategy for Pemphigus

8:40 a.m. – 8:55 a.m.

Discussion

8:55 a.m. – 9:20 a.m.

Michael Rosenblum, M.D., Ph.D.

Professor of Dermatology, UC-San Francisco

Immune Regulation in Skin

9:20 a.m. – 9:35 a.m.	Discussion
9:35 a.m. – 10 a.m.	<p>Megan Levings, Ph.D. Professor of Surgery, University of British Columbia Investigator and Lead – Childhood Diseases, BC Children’s Hospital <i>Inducing tolerance with regulatory T cell therapy</i></p>
10 a.m. – 10:15 a.m.	Discussion
10:15 a.m. – 10:30 a.m.	Coffee Break
10:30 a.m. – 10:55 a.m.	<p>Michel Enamorado, Ph.D. Assistant Professor of Dermatology, Mount Sinai Medical Center <i>Wired and Guarded: The Neuroimmune Landscape of the Skin</i></p>
10:55 a.m. – 11:10 a.m.	Discussion
11:10 a.m. – 11:25 a.m.	<p>Poppy Gould, Ph.D. Postdoctoral Research Fellow at NYU Langone Health <i>Restoring aberrant CD74 signaling in hidradenitis suppurativa keratinocytes with Plerixafor treatment</i></p>
11:25 a.m. – 11:40 a.m.	<p>Ichiro Imanishi, DVM, Ph.D. Postdoctoral Fellow, Icahn School of Medicine, Mount Sinai <i>Spatial Transcriptomic Mapping Reveals a Basophil–Fibroblast Circuit Driving Chronic Type 2 Dermatitis</i></p>
11:40 a.m. – 11:55 a.m.	<p>Cristina de Guzman Strong, Ph.D. Associate Scientist, Center for Cutaneous Biology and Immunology, Department of Dermatology, Henry Ford Health, Associate Professor, Department of Medicine, College of Human Medicine, Michigan State University <i>Translating knowledge of human skin evolution and genetic innovation to develop new treatments for the skin barrier</i></p>
Noon – 4:30 p.m.	<p>Lunch (On Your Own)</p> <p>FREE TIME / CASCADE HIKE</p>
4:30 p.m. – 6 p.m.	<p>Mentorship Mixer and Reverse Expo</p> <p>Appetizers Served</p>

6 p.m. – 7:30 p.m.

Dinner

Poster Competition Awards

7:30 p.m. – 8:30 p.m.

Keynote

Jay P. Siegel, M.D.

Member, National Academies' Forum – Regenerative Medicine

Former Director of Office of Therapeutics, FDA CBER

Former Chief Biotechnology Officer, Johnson & Johnson

Reflections on the regulation and development of cell-based and other advanced biologic therapies

We will discuss the historical basis for and development of the regulatory paradigm for human tissue, cell, & gene therapies; genesis and nature of FDA programs to accelerate development of such therapies, and genesis and functions of the NASEM Forum on Regenerative Medicines.

Sunday, October 19

7 a.m. – 8 a.m.

Breakfast

8 a.m. – 8:05 a.m.

Announcements

8:05 a.m. – 8:15 a.m.

Session 4:

Novel Cancer Therapeutics for Cutaneous Oncology

Session Moderator: **Niro Anandasabapathy, M.D., Ph.D.**

Associate Professor of Dermatology, Weill Cornell Medicine

This session highlights emerging novel cancer therapy platforms that address gaps in knowledge regarding these future therapies. Understanding the mechanistic basis of novel cancer therapeutics and patient responses will help generate new and more effective technologies.

8:15 a.m. – 8:40 a.m.

Niro Anandasabapathy, M.D., Ph.D.

Associate Professor of Dermatology, Weill Cornell Medicine

PD-1 and memory T cells, a smoking gun in ICB cancer efficacy and toxicity

8:40 a.m. – 8:55 a.m.

Discussion

8:55 a.m. – 9:20 a.m.

Y. Erin Chen, M.D., Ph.D.

Assistant Professor of Biology and Core Member, Massachusetts Institute of Technology and Broad Institute

Attending Dermatologist, Massachusetts General Hospital

How are commensal skin bacteria sensed by the immune system?

9:20 a.m. – 9:35 a.m. Discussion

9:35 a.m. – 10 a.m.

Derin Keskin, Ph.D.
Principal Scientist, Dana Farber Cancer Institute, Harvard University
Immunogenic Personal Neoepitopes for Improving Cancer Therapies

10 a.m. – 10:15 a.m. Discussion

10:15 a.m. – 10:30 a.m. Coffee Break

10:30 a.m. – 10:55 a.m.

Anne Lynn Chang, M.D.
Professor of Dermatology, Stanford University
Clinical trials for non-melanoma skin cancers

10:55 a.m. – 11:10 a.m. Discussion

11:10 a.m. – 11:25 a.m.

Bojing Jia, Ph.D.
M.D./Ph.D Student, University of California San Diego
Spatial Genome Alignment: a spatial multi-omic technology for epigenetic mapping with dermatologic applications

11:25 a.m. – 11:40 a.m.

Kasidy Brown, B.S.
Ph.D Student, Oregon Health & Science University
Dendritic cell intrinsic androgen receptor signaling inhibits anti-tumor immunity in melanoma

11:40 a.m. – 11:55 a.m.

Joel Sunshine, M.D., Ph.D., M.S.
Assistant Professor of Dermatology, Pathology, Oncology, and Biomedical Engineering, Johns Hopkins University School of Medicine
Non-viral gene delivery to restore antigen presentation in melanoma

Noon – 1:15 p.m.

Lunch
Industry Leaders Panel #2: *Research Idea to Improving Lives: Acceleration through Dermatologic Indications*

(Key takeaways Include: How and why skin diseases represent an attractive first indication for companies developing novel therapeutics.)

- Facilitator: **William Ju, M.D.**, President, Advancing Innovation in Dermatology
- Panelists:
Vishwas Seshadri, Ph.D., M.B.A., Chief Executive Officer, Director, Abeona Therapeutics
Jennifer Saam, Ph.D., Executive Director of Medical Affairs, Castle Bioscience
Daphne Chan, PhD, MHEcon, Head of Dermatology Medical Affairs, Johnson & Johnson

1:15 p.m. – 1:25 p.m.

Session 5:

RNA Medicines for Cutaneous Disorders

Session Moderator: **Alain Hovnanian, M.D., Ph.D.**

Professor of Genetics, University of Paris

Laboratory Director, Institut Imagine, INSERM

This exciting final session focuses on the dramatic shift in research, clinical development, and commercial activity to exploit the many physiological roles of RNA for use in medicine. These include RNA vaccines, siRNAs, circular RNAs, and splice site modifiers for cancer, immunomodulation and genodermatoses. Identifying targets and manufacturing clinical scale RNA therapies remains a gap in knowledge.

1:25 p.m. – 1:50 p.m.

Alain Hovnanian, M.D., Ph.D.

Professor of Genetics, University of Paris

Laboratory Director, Institut Imagine, INSERM

Splice-modulating strategies for treating skin diseases

1:50 p.m. – 2:05 p.m.

Discussion

2:05 p.m. – 2:30 p.m.

John Harris, M.D., Ph.D.

Lancer Endowed Chair in Dermatology, Massachusetts General Brigham

From Nobel discoveries to clinical breakthrough: How RNA interference is transforming treatments for inflammatory skin diseases

2:30 p.m. – 2:45 p.m.

Discussion

2:45 p.m. – 3:10 p.m.

William Greenleaf, Ph.D.

Professor of Genetics, Stanford University

Dissecting developmental programs and distal regulation with large-scale, single cell open chromatin data sets

3:10 p.m. – 3:25 p.m.

Discussion

3:25 p.m. – 3:40 p.m.

Jinwoo Lee, M.D., Ph.D., FAAD

Instructor, Department of Dermatology, Stanford

Novel autoantibodies target hotspots on the XIST ribonucleoprotein complex in female-biased autoimmune diseases

3:40 p.m. – 3:55 p.m.

Richard Wang M.D., Ph.D.

Professor of Dermatology, University of Colorado Anschutz Medical Campus

Advancing Lipid Nanoparticle (LNP)-mRNA and LNP-siRNA Therapies Using In Vivo Models of Xeroderma Pigmentosum and Psoriasis

5 p.m. – 7:30 p.m.

Salmon Bake Dinner

*Offsite (weather permitting)
Shuttle departs at 5 p.m. from the lobby and returns at 7:30 p.m.*

Monday, October 20

7 a.m. – 8 a.m.

Breakfast and Depart

8:30 a.m.

Bus Departs for PDX Airport

Acknowledgements

Funding for this conference was made possible (in part) by a grant (5R13AR009431-58) from the **National Institute of Arthritis and Musculoskeletal and Skin Diseases**. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

The Montagna Symposium on the Biology of Skin gratefully acknowledges:

- NIH Grant Number 2 R13 AR009431-58 from the **National Institute of Arthritis and Musculoskeletal and Skin Diseases**
- **Society for Investigative Dermatology (SID)** for the **SID Eugene M. Farber Travel Awards for Young Investigators**
- **Japanese Society for Investigative Dermatology (JSID)** for the **JSID Travel Awards for Young Investigators**
- **Taiwanese Society for Investigative Dermatology (TSID)** for the **TSID Travel Awards for Young Investigators**
- **Korean Society for Investigative Dermatology (KSID)** for the **KSID Travel Awards for Young Investigators**
- **European Society of Dermatologic Research (ESDR)** for the **ESDR Travel Awards**
- *Journal of Investigative Dermatology*

The 2025 Symposium is supported by the LEO Foundation (Grant #LF-RN-25-601068)	
The 2025 Symposium is supported by a charitable gift from the David M.C. Ju Foundation	
The 2025 Symposium is supported by the Epidermolysis Bullosa Medical Research Foundation (EBMRF)	
The 2025 Symposium is supported by the EB Research Partnership	
The 2025 Montagna Symposium is supported by The Biology of Skin Foundation	
The 2025 Symposium is supported through an educational grant from Abbvie	

2025 Montagna Symposium on the Biology of Skin Sponsors

Champion Level




Sustainer Level

Johnson & Johnson

Benefactor Level



Patron Level



sanofi

Associate Level

SKINMEDICA®

